Search Results

DiaCarta, Inc. today announced that it has established a strategic collaboration with OncoAssure Ltd, an Irish medical diagnostics company.

DiaCarta, Inc. (“DiaCarta”), a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector.

DiaCarta, Inc. announced that DiaCarta received US FDA 510 clearance for it’s over the counter at home iColon Fecal Occult Blood Test that enables early detection of blood in stool at home, which is clinically relevant in gastrointestinal disorders and colorectal cancer.

DiaCarta proudly announced that the Oncuria® Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.

DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund.

DiaCarta, a leading molecular diagnostics company personalizing patient care through liquid biopsy, proudly announced that its revolutionary RadTox™ test, designed for tumor response monitoring, is now eligible for reimbursement from Medicare, effective January 1, 2024.

AnchorDx announced that it has entered into a long-term collaboration with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, for product development and global commercialization in the cancer screening arena.

DiaCarta, Ltd. today announced the termination of its Business Combination Agreement with HH&L Acquisition Co.

DiaCarta, Ltd., a novel molecular diagnostic test developer for cancer and infectious diseases, announced that it has received accreditation by the College of American Pathologists for its CLIA certified lab.

DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, and Nonagen Bioscience Corporation (“Nonagen”), a cancer diagnostics company, today announced the successful completion of the validation study of Oncuria® multiplex bladder cancer immunoassay as a laboratory developed test (“LDT”).